Roth Capital Starts Concert Pharmaceuticals (CNCE) at Buy
Tweet
Share
E-mailGet Alerts CNCE Hot Sheet
Price: $8.37 --0%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Roth Capital initiates coverage on Concert Pharmaceuticals (NASDAQ: CNCE) with a Buy rating and a price target of $28.00.
For an analyst ratings summary and ratings history on Concert Pharmaceuticals click here. For more ratings news on Concert Pharmaceuticals click here.
Shares of Concert Pharmaceuticals closed at $14.10 yesterday.
For an analyst ratings summary and ratings history on Concert Pharmaceuticals click here. For more ratings news on Concert Pharmaceuticals click here.
Shares of Concert Pharmaceuticals closed at $14.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Craig-Hallum Starts Alterity Therapeutics (ATHE) at Buy
- Piper Sandler Starts Mercury Systems (MRCY) at Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
